Exhibit
10.27


 


Fifth
Amendment to Transaction Documents


 


This
Fifth Amendment to the Transaction (this “Amendment”) is effective as of November 16, 2022 (“Effective Date”),
by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology,
Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite
110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used
herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as
amended, entered between the Parties (the “Securities Purchase Agreement”)


 


Recitals


 


WHEREAS,
pursuant to the Transaction Documents, Puritan Partners purchased a 12.5% Original Issue Discount Senior Secured Note in the
principal amount of $1,142,857.14 due March 2, 2023 ( as amended, the “Note”) and was issued a common stock purchase
warrant to purchase 22,857,143 shares of the common stock at $0.0001 exercise price ( as amended, the
“Warrant”);


 


WHEREAS, Puritan
Partners and Company are parties to the Transaction Documents, which were previously amended on August 18, 2022 , October 2, 2022,
October 14, 2022, and November 2, 2022, and the parties now desire to further amend the respective Transaction Documents in
accordance with the terms of this Amendment.


 


NOW,
THEREFORE, in consideration of the following and other consideration, the receipt of which is hereby acknowledged, the parties agree
as follows:


 


		a)	Monthly
                                            Redemption Date. The definition of “Monthly Redemption Date” set forth in Section
1 of the Note is deleted in its entirety and hereby replaced with the following:






 


“Monthly
Redemption Date” means the second of each month, commencing immediately upon December 17, 2022, and terminating upon the full
redemption of this Note. Provided however that upon completion of a Qualified Offering, the entire outstanding balance of the Note will
be due and payable at closing of the Qualified Offering.


 


		(b)	Monthly
                                            Redemption Amount. The definition of “Monthly Redemption Amount” set forth in
                                            Section 1 of the Note is deleted in its entirety and hereby replaced with the following:




 


“Monthly
Redemption Amount” means, as to a Monthly Redemption, one fourth of the original principal amount at 110% of such principal
amount, plus accrued but unpaid interest, liquidated damages and any other amounts then owing to the Holder in respect of this Note.




 


		(c)	The
                                            interest on the Note that is due and payable on December 2, 2022 as well as any other unpaid
                                            accrued and unpaid interest, shall instead be due and payable on the earlier of (i) December
                                            17, 2022 and (ii) the closing of the Qualified Offering.

	 	 	 
	 	(d)	In
                                            further consideration for extending by one month the straight-line amortization payment requirement
                                            under the Note, the Company agrees that (i) the number of shares underlying the Warrant shall
                                            be increased from 26,666,667 shares to 28,571,429shares (which amount may be subject to adjustment
                                            per the terms of the Warrant) and (ii) upon the closing of Company’s offering being
                                            registered pursuant to the S-1 Registration Statement (Registration. No. 333-264339), the
                                            outstanding principal balance, along with any accrued interest, fees or costs, will be repaid,
                                            in full pursuant to either the Optional Redemption provisions contained in Section 5(a) of
                                            the Note or the Mandatory Prepayment provisions contained in Section 5(d) of the Note, as
                                            the case may be.




 






    	 



     


    

 


Each
of the undersigned has caused this Amendment to be duly executed and delivered as of the date first written above and will become effective
as of the Effective Date.


 


	 	CURATIVE BIOTECHNOLOGY, INC.
	 	 	 
	 	By:	 
	 	Name:	Richard
    Garr                  
	 	Title:	Chief
    Executive Officer


 


	 	Puritan Partners LLC
	 	 	 
	 	By:	
	 	Name:	Richard
    Smithline
	 	Title:	Managing
    Member